ERBB2 and breast carcinoma: Taken together, our findings unveil USP2 as a guardian of ErbB2 abundance in ErbB2-positive breast cancers, with its DUB activity required to antagonize the endocytic degradation of ErbB2 under steady state conditions (Fig. 8).